Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs SUMATRIPTAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve transmission.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Acute treatment of migraine with or without aura,Acute treatment of cluster headache episodes
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Sumatriptan is available as oral tablets (25 mg, 50 mg, 100 mg), subcutaneous injection (6 mg/0.5 m L), and nasal spray (5 mg, 20 mg). For acute migraine: oral: 50-100 mg at onset, may repeat after 2 hours (max 200 mg/day). Subcutaneous: 6 mg at onset, may repeat after 1 hour (max 12 mg/24h). Nasal spray: 20 mg in one nostril at onset, may repeat after 2 hours (max 40 mg/day).
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
2.5 hours (range 1–4 h); clinically relevant for redosing interval of ≥2 h.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily via monoamine oxidase A (MAO-A); minor via cytochrome P450 (CYP) enzymes.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
60% renal (as indole acetic acid metabolite), 40% fecal; <3% unchanged in urine.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
14–21%, primarily to albumin and alpha-1-acid glycoprotein.
4-6 L/kg; large Vd indicates extensive tissue distribution
2.0–3.3 L/kg; indicates extensive tissue distribution.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Oral: 15% (due to first-pass metabolism); subcutaneous: 97%; intranasal: 17% (with variability).
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No specific dose adjustment is recommended for renal impairment. However, sumatriptan and its metabolites are excreted renally, and caution is advised in severe renal impairment (Cr Cl <15 m L/min). No specific GFR-based guidelines are established.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Contraindicated in severe hepatic impairment (Child-Pugh C). For mild to moderate hepatic impairment (Child-Pugh A or B): oral maximum dose is 50 mg; nasal spray: 5 mg single dose; subcutaneous: no specific adjustment, but caution advised due to reduced clearance.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Not approved for pediatric use <18 years. However, off-label: adolescent (12-17 years): oral 25-100 mg at onset, may repeat after 2 hours (max 200 mg/day). Subcutaneous: 3-6 mg at onset (based on weight, e.g., 0.06 mg/kg). Nasal spray: 5-20 mg at onset.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Limited data in elderly. Start with the lowest effective dose (e.g., oral 25 mg, subcutaneous 3 mg, nasal spray 5 mg). Caution due to potential for cardiovascular risk, hypertension, and reduced hepatic/renal function. Avoid in patients with uncontrolled hypertension or ischemic heart disease.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Not recommended for use in patients with risk factors for coronary artery disease (e.g., hypertension, diabetes, smoking) unless a cardiovascular evaluation confirms absence of coronary artery disease.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Risk of myocardial ischemia, infarction, and Prinzmetal's angina,Life-threatening serotonin syndrome with concomitant serotonergic drugs,Elevations in blood pressure,Increased risk of cerebrovascular events,Overuse headache with frequent use
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Ischemic heart disease,History of myocardial infarction,Uncontrolled hypertension,Hemiplegic or basilar migraine,Concomitant use of MAO-A inhibitors or within 2 weeks of discontinuation,Severe hepatic impairment,Hypersensitivity to sumatriptan
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
No significant food interactions. Avoid alcohol during migraine attacks as it can worsen headaches. May be taken with or without food.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
FDA Pregnancy Category C. In first trimester, no increased risk of major congenital malformations from available data; however, animal studies show embryo lethality and increased malformations at high doses. Second and third trimester risks include potential for uterine hypertonus and fetal hypoxia during maternal use for migraine attacks; avoid during third trimester due to risk of premature uterine contractions.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Sumatriptan is excreted into human breast milk with a relative infant dose of 3.5% of maternal weight-adjusted dose (M/P ratio approximately 0.6-4.3). Clinical studies show no adverse effects in breastfed infants; however, wait at least 12 hours after injection or 24 hours after oral dose to breastfeed to minimize exposure.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
No specific dose adjustments required for pregnancy based on pharmacokinetic changes; however, lower starting doses may be considered due to increased sensitivity to vascular effects. Avoid use in preeclampsia or uncontrolled hypertension.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Sumatriptan is a 5-HT1B/1D receptor agonist used for acute migraine. It is available in oral, nasal, subcutaneous, and rectal formulations. Onset of action is fastest with subcutaneous injection (10-15 minutes). Avoid use within 24 hours of other triptans or ergot alkaloids. Contraindicated in patients with ischemic heart disease, cerebrovascular disease, uncontrolled hypertension, or hemiplegic/basilar migraine. Monitor for serotonin syndrome when combined with SSRIs/SNRIs.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
Take sumatriptan at the first sign of migraine headache for best results.,Do not exceed the recommended dose: maximum 100 mg orally or 20 mg intranasally per single dose, with a maximum of 200 mg daily for oral formulations.,Seek emergency medical attention if you experience chest pain, shortness of breath, irregular heartbeat, or signs of stroke.,Avoid driving or operating machinery until you know how sumatriptan affects you, as it may cause dizziness or drowsiness.,Inform your doctor if you have heart disease, high blood pressure, or are pregnant or breastfeeding.
No interactions on record
"Concurrent use of sumatriptan, a serotonin 5-HT1B/1D receptor agonist, and rasagiline, a selective monoamine oxidase B (MAO-B) inhibitor, can lead to serotonin syndrome due to excessive serotonergic activity in the central nervous system. Rasagiline inhibits the metabolism of serotonin, while sumatriptan indirectly increases serotonin release; their combination may result in life-threatening neuromuscular excitation, autonomic instability, and altered mental status. Symptoms may include hyperthermia, rigidity, myoclonus, and rapid fluctuations in vital signs, requiring immediate medical intervention."
"Sumatriptan, a 5-HT1B/1D receptor agonist used for migraine, and sulpiride, a dopamine D2 receptor antagonist with atypical antipsychotic properties, may exhibit additive or synergistic effects on the central nervous system. This combination can potentially increase the risk of serotonin syndrome (due to sumatriptan's serotonergic activity) and may also lead to enhanced extrapyramidal symptoms or neuroleptic malignant syndrome via combined dopaminergic antagonism. Clinical outcomes may include hyperthermia, rigidity, altered mental status, and autonomic instability."
"The combination of sumatriptan (a 5-HT1B/1D receptor agonist) and paroxetine (a selective serotonin reuptake inhibitor) increases the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. This interaction is due to additive serotonergic effects, as both drugs enhance serotonin activity in the central nervous system. Clinical outcomes range from mild symptoms (tremor, hyperreflexia, diaphoresis) to severe manifestations (hyperthermia, rigidity, seizures) and require immediate medical attention."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs SUMATRIPTAN, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. SUMATRIPTAN is a 5-HT1 Agonist that works by Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and SUMATRIPTAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of SUMATRIPTAN is: Sumatriptan is available as oral tablets (25 mg, 50 mg, 100 mg), subcutaneous injection (6 mg/0.5 m L), and nasal spray (5 mg, 20 mg). For acute migraine: oral: 50-100 mg at onset, may repeat after 2 hours (max 200 mg/day). Subcutaneous: 6 mg at onset, may repeat after 1 hour (max 12 mg/24h). Nasal spray: 20 mg in one nostril at onset, may repeat after 2 hours (max 40 mg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and SUMATRIPTAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. SUMATRIPTAN is classified as Category D/X. FDA Pregnancy Category C. In first trimester, no increased risk of major congenital malformations from available data; however, animal studies show embryo lethality and increased m. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.